

# Cristina Rodriguez-Antona

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1797106/publications.pdf>

Version: 2024-02-01

142  
papers

8,574  
citations

53794

45  
h-index

60623

81  
g-index

145  
all docs

145  
docs citations

145  
times ranked

12752  
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoeipigenetic and clinical aspects. , 2007, 116, 496-526.		990
2	Cytochrome P450 pharmacogenetics and cancer. <i>Oncogene</i> , 2006, 25, 1679-1691.	5.9	492
3	Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. <i>Nature Genetics</i> , 2011, 43, 663-667.	21.4	478
4	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
5	Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. <i>Xenobiotica</i> , 2002, 32, 505-520.	1.1	340
6	Tumoral and tissue-specific expression of the major human $\beta$ -tubulin isotypes. <i>Cytoskeleton</i> , 2010, 67, 214-223.	2.0	221
7	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. <i>Lancet Oncology</i> , The, 2011, 12, 1143-1150.	10.7	217
8	The miR-200 family controls $\beta$ -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. <i>Endocrine-Related Cancer</i> , 2010, 18, 85-95.	3.1	188
9	Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas. <i>Molecular Endocrinology</i> , 2010, 24, 2382-2391.	3.7	179
10	Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	143
11	Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. <i>Human Molecular Genetics</i> , 2013, 22, 2169-2176.	2.9	142
12	The Variant rs1867277 in FOXE1 Gene Confers Thyroid Cancer Susceptibility through the Recruitment of USF1/USF2 Transcription Factors. <i>PLoS Genetics</i> , 2009, 5, e1000637.	3.5	140
13	Cytochrome P-450 mRNA Expression in Human Liver and Its Relationship with Enzyme Activity. <i>Archives of Biochemistry and Biophysics</i> , 2001, 393, 308-315.	3.0	129
14	Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. , 1998, 177, 553-562.		125
15	Genetics of Pheochromocytoma and Paraganglioma in Spanish Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1701-1705.	3.6	120
16	Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. <i>Pharmacogenomics Journal</i> , 2011, 11, 121-129.	2.0	112
17	Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). <i>Annals of Oncology</i> , 2015, 26, 1987-1993.	1.2	112
18	Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. <i>Human Genetics</i> , 2010, 127, 1-17.	3.8	110

#	ARTICLE	IF	CITATIONS
19	Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. <i>Endocrine-Related Cancer</i> , 2010, 17, 7-16.	3.1	108
20	Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2005, 360, 1563-1570.	4.0	106
21	Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients. <i>Journal of Medical Genetics</i> , 2015, 52, 647-656.	3.2	102
22	Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. <i>Biochemical and Biophysical Research Communications</i> , 2006, 341, 451-458.	2.1	98
23	Transcriptional Regulation of Human CYP3A4 Basal Expression by CCAAT Enhancer-Binding Protein $\beta$ and Hepatocyte Nuclear Factor-3 $\beta$ . <i>Molecular Pharmacology</i> , 2003, 63, 1180-1189.	2.3	97
24	Quantitative RT-PCR Measurement of Human Cytochrome P-450s: Application to Drug Induction Studies. <i>Archives of Biochemistry and Biophysics</i> , 2000, 376, 109-116.	3.0	93
25	Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. <i>Biochemical and Biophysical Research Communications</i> , 2005, 338, 299-305.	2.1	93
26	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e86263.	2.5	76
27	CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 68, 621-629.	1.9	75
28	GrossSDHB deletions in patients with paraganglioma detected by multiplex PCR: A possible hot spot?. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 213-219.	2.8	73
29	Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. <i>Annals of Oncology</i> , 2013, 24, 2409-2414.	1.2	73
30	Gain-of-function mutations in DNMT3A in patients with paraganglioma. <i>Genetics in Medicine</i> , 2018, 20, 1644-1651.	2.4	73
31	Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 16.	3.7	72
32	Deregulated miRNAs in Hereditary Breast Cancer Revealed a Role for miR-30c in Regulating KRAS Oncogene. <i>PLoS ONE</i> , 2012, 7, e38847.	2.5	71
33	Molecular characterisation of a common SDHB deletion in paraganglioma patients. <i>Journal of Medical Genetics</i> , 2007, 45, 233-238.	3.2	69
34	Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. <i>Journal of Medical Genetics</i> , 2013, 50, 599-605.	3.2	67
35	Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. <i>Genetics in Medicine</i> , 2018, 20, 622-629.	2.4	66
36	PheoSeq. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 575-588.	2.8	63

#	ARTICLE	IF	CITATIONS
37	Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. <i>FEBS Journal</i> , 2001, 268, 1448-1459.	0.2	62
38	Regulatory Polymorphisms in $\beta$ -Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy. <i>Clinical Cancer Research</i> , 2012, 18, 4441-4448.	7.0	61
39	Whole-Exome Sequencing Reveals Defective <i>CYP3A4</i> Variants Predictive of Paclitaxel Dose-Limiting Neuropathy. <i>Clinical Cancer Research</i> , 2015, 21, 322-328.	7.0	61
40	Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. <i>Pharmacogenomics Journal</i> , 2008, 8, 268-277.	2.0	59
41	Pharmacogenomic biomarkers for personalized cancer treatment. <i>Journal of Internal Medicine</i> , 2015, 277, 201-217.	6.0	57
42	Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates. <i>Biomedicines</i> , 2020, 8, 94.	3.2	57
43	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.9	54
44	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. <i>Theranostics</i> , 2019, 9, 4946-4958.	10.0	54
45	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. <i>Clinical Cancer Research</i> , 2015, 21, 3020-3030.	7.0	53
46	Identification and phenotype characterization of two haplotypes causing different enzymatic capacity in fetal livers. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 259-270.	4.7	52
47	Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. <i>Endocrine-Related Cancer</i> , 2013, 20, 477-493.	3.1	52
48	Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. <i>American Journal of Human Genetics</i> , 2019, 104, 651-664.	6.2	51
49	Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on <i>MT-RNR1</i> Genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 366-372.	4.7	50
50	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019, 79, 505-517.	0.9	49
51	High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. <i>Pharmacogenomics Journal</i> , 2015, 15, 288-292.	2.0	48
52	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. <i>Genetics in Medicine</i> , 2018, 20, 1652-1662.	2.4	45
53	Transcriptional Regulation of the Human CYP2A6 Gene. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 814-822.	2.5	44
54	Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. <i>European Journal of Human Genetics</i> , 2009, 17, 991-998.	2.8	43

#	ARTICLE	IF	CITATIONS
55	Pharmacogenomics of paclitaxel. <i>Pharmacogenomics</i> , 2010, 11, 621-623.	1.3	43
56	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	7.0	43
57	Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. <i>Blood</i> , 2007, 110, 3345-3351.	1.4	42
58	Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. <i>Human Mutation</i> , 2007, 28, 613-621.	2.5	41
59	Rationalization of Genetic Testing in Patients with Apparently Sporadic Pheochromocytoma/Paraganglioma. <i>Hormone and Metabolic Research</i> , 2009, 41, 672-675.	1.5	41
60	Detection of the first gross CDC73 germline deletion in an HPTâ€¦T syndrome family. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 922-929.	2.8	41
61	Oxaliplatin induced-neuropathy in digestive tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 166-178.	4.4	40
62	Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. <i>JCI Insight</i> , 2016, 1, e86051.	5.0	39
63	<i>SDHC</i> mutation in an elderly patient without familial antecedents. <i>Clinical Endocrinology</i> , 2008, 69, 906-910.	2.4	37
64	Allelic variant at âˆ²79 (C&gt;T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels. <i>Endocrine-Related Cancer</i> , 2010, 17, 317-328.	3.1	35
65	Differential Gene Expression of Medullary Thyroid Carcinoma Reveals Specific Markers Associated with Genetic Conditions. <i>American Journal of Pathology</i> , 2013, 182, 350-362.	3.8	35
66	IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. <i>British Journal of Cancer</i> , 2015, 112, 1190-1198.	6.4	35
67	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. <i>British Journal of Cancer</i> , 2020, 123, 793-802.	6.4	35
68	Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. <i>Endocrine-Related Cancer</i> , 2007, 14, 645-654.	3.1	34
69	<i>CYP2D6</i> genotyping for psychiatric patients treated with risperidone: considerations for costâ€¦effectiveness studies. <i>Pharmacogenomics</i> , 2009, 10, 685-699.	1.3	34
70	Cytochrome P450 2D6 Genotyping. <i>CNS Drugs</i> , 2009, 23, 181-191.	5.9	33
71	A nicotineC-oxidase gene (CYP2A6) polymorphism important for promoter activity. <i>Human Mutation</i> , 2004, 23, 258-266.	2.5	32
72	Hsaâ€¦miRâ€¦139â€¦5p is a prognostic thyroid cancer marker involved in HNRNPFâ€¦mediated alternative splicing. <i>International Journal of Cancer</i> , 2020, 146, 521-530.	5.1	29

#	ARTICLE	IF	CITATIONS
73	Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. <i>Modern Pathology</i> , 2020, 33, 2580-2590.	5.5	29
74	Polymorphic NF- $\gamma$ dependent regulation of human nicotine C-oxidase (CYP2A6). <i>Pharmacogenetics and Genomics</i> , 2004, 14, 369-379.	5.7	28
75	Genetic variation in the <i>SLC19A1</i> gene and methotrexate toxicity in rheumatoid arthritis patients. <i>Pharmacogenomics</i> , 2012, 13, 1583-1594.	1.3	27
76	Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 385-394.	2.5	27
77	Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. <i>PLoS ONE</i> , 2017, 12, e0180192.	2.5	27
78	Hematologic $\beta$ -Tubulin VI Isoform Exhibits Genetic Variability That Influences Paclitaxel Toxicity. <i>Cancer Research</i> , 2012, 72, 4744-4752.	0.9	26
79	Functional and in silico assessment of MAX variants of unknown significance. <i>Journal of Molecular Medicine</i> , 2015, 93, 1247-1255.	3.9	25
80	Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. <i>BMC Cancer</i> , 2017, 17, 63.	2.6	25
81	Collaboration with other firms and customers: innovation's secret weapon. <i>Strategy and Leadership</i> , 2004, 32, 16-20.	0.5	24
82	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	2.8	23
83	A Novel Polymorphic Cytochrome P450 Formed by Splicing of CYP3A7 and the Pseudogene CYP3AP1. <i>Journal of Biological Chemistry</i> , 2005, 280, 28324-28331.	3.4	22
84	Impact of genetic polymorphisms in <i>CYP2C8</i> and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. <i>Pharmacogenomics</i> , 2008, 9, 277-288.	1.3	22
85	Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. <i>Pharmacogenomics Journal</i> , 2017, 17, 42-46.	2.0	21
86	Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy. <i>Oncologist</i> , 2019, 24, e784-e792.	3.7	20
87	P-glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 671-680.	4.7	20
88	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1477-1484.	1.9	19
89	The hematopoietic-specific $\beta$ 1-tubulin is naturally resistant to 2-Methoxyestradiol and protects patients from drug-induced myelosuppression. <i>Cell Cycle</i> , 2009, 8, 3914-3924.	2.6	18
90	Molecular Markers to Predict Response to Therapy. <i>Seminars in Oncology</i> , 2013, 40, 444-458.	2.2	18

#	ARTICLE	IF	CITATIONS
91	VEGF, VEGFR3, and PDGFRB Protein Expression Is Influenced by <i>RAS</i> Mutations in Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2014, 24, 1251-1255.	4.5	18
92	Biallelic <i>TSC2</i> Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 352-358.	4.9	18
93	Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2013, 20, 611-619.	3.1	17
94	Role of cytochrome P450 <i>CYP2C8</i> ( <i>CYP2C8</i> ) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. <i>Pharmacogenomics</i> , 2015, 16, 929-937.	1.3	17
95	Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR -Activating Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1310-1315.	4.9	16
96	Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy. <i>Clinical Cancer Research</i> , 2017, 23, 1227-1235.	7.0	16
97	A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. <i>Oncologist</i> , 2019, 24, e1024-e1033.	3.7	16
98	MicroRNAs Targeting HIF-2 $\alpha$ , VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2 $\alpha$ Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3099.	3.7	16
99	Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. <i>Gene</i> , 2012, 506, 62-68.	2.2	15
100	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018, 47, 450-459.	1.9	15
101	Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis. <i>Analytical Biochemistry</i> , 2009, 389, 74-76.	2.4	14
102	Association between SLC19A1 gene polymorphism and high dose methotrexate toxicity in childhood acute lymphoblastic leukaemia and non Hodgkin malignant lymphoma: introducing a haplotype based approach. <i>Radiology and Oncology</i> , 2017, 51, 455-462.	1.7	14
103	PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. <i>International Journal of Cancer</i> , 2020, 146, 1435-1444.	5.1	14
104	Analysis of Telomere Maintenance Related Genes Reveals NOP10 as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma. <i>Cancers</i> , 2021, 13, 4758.	3.7	14
105	Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 41-48.	1.5	13
106	Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation. <i>BMC Cancer</i> , 2018, 18, 561.	2.6	13
107	Progress in pharmacogenetics: consortiums and new strategies. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 17-23.	0.6	12
108	Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. <i>Cancer Treatment Reviews</i> , 2018, 70, 209-222.	7.7	12

#	ARTICLE	IF	CITATIONS
109	Sunitinib and Evofosfamide (<sc>TH</sc>-302) in Systemic Treatment-Na <sup>+</sup> ve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The <sc>GETNE</sc>-1408 Trial. <i>Oncologist</i> , 2021, 26, 941-949.	3.7	12
110	Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma. <i>Pharmacogenomics</i> , 2012, 13, 1621-1633.	1.3	11
111	Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 179-186.	1.6	10
112	Human genetics: international projects and personalized medicine. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 3-8.	0.6	10
113	Circulating Levels of the Interferon- $\gamma$ -Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. <i>Cancers</i> , 2021, 13, 2849.	3.7	10
114	Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data. <i>Npj Genomic Medicine</i> , 2022, 7, 12.	3.8	10
115	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxelâ€”Letter. <i>Clinical Cancer Research</i> , 2015, 21, 3092-3093.	7.0	9
116	Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancerâ€”GEnetic- and tumor-related biomarkers for response and toxicity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 529.e9-529.e16.	1.6	9
117	MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1554.	3.7	9
118	Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma. <i>Genetics in Medicine</i> , 2021, 23, 698-704.	2.4	9
119	SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. <i>Pharmacogenomics</i> , 2016, 17, 463-471.	1.3	8
120	A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2350-2356.	7.0	7
121	Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia. <i>Pharmacogenomics Journal</i> , 2020, 20, 179-191.	2.0	7
122	Meta-analysis on the association of <i>VEGFR1</i> genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 1204-1212.	1.8	6
123	Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 227-231.	1.5	5
124	Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing. <i>Lung Cancer</i> , 2020, 147, 106-114.	2.0	5
125	Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma. <i>Cancers</i> , 2020, 12, 3304.	3.7	5
126	CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3548-3561.	3.6	5



#	ARTICLE	IF	CITATIONS
127	MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. <i>PLoS ONE</i> , 2020, 15, e0238809.	2.5	5
128	A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCulating Endothelial cells) Study (SOGUG-CEC-2011-01). <i>European Urology Focus</i> , 2017, 3, 430-436.	3.1	4
129	Overexpression of miR-483-5p is confined to metastases and linked to high circulating levels in patients with metastatic pheochromocytoma/paraganglioma. <i>Clinical and Translational Medicine</i> , 2020, 10, e260.	4.0	4
130	mTOR Pathway Mutations and Response to Rapalogs in RCC Letter. <i>Clinical Cancer Research</i> , 2017, 23, 5320-5320.	7.0	3
131	Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS503-TPS503.	1.6	3
132	The role of pharmacogenetics and pharmacogenomics in 21st-century medicine: state of the art and new challenges discussed in the VII Conference of the Spanish Pharmacogenetics and Pharmacogenomics Society (SEFF). <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 1-2.	0.6	2
133	MicroRNAs as potential predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 640.e23-640.e29.	1.6	2
134	Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. <i>Cancers</i> , 2022, 14, 2838.	3.7	1
135	Microtubule-targeting drugs and personalization of cancer treatment. <i>Pharmacogenomics</i> , 2011, 12, 449-451.	1.3	0
136	A Novel Approach for the Identification of Pharmacogenetic Variants in MT-RNR1 through Next-Generation Sequencing Off-Target Data. <i>Journal of Clinical Medicine</i> , 2020, 9, 2082.	2.4	0
137	Abstract P3-07-40: Pharmacogenetic study of exemestane and everolimus in metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors. , 2016, , .		0
138	Title is missing!. , 2020, 15, e0238809.		0
139	Title is missing!. , 2020, 15, e0238809.		0
140	Title is missing!. , 2020, 15, e0238809.		0
141	Title is missing!. , 2020, 15, e0238809.		0
142	The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What's next? An urgent clinical unmet need for patients. <i>Drug Metabolism and Drug Interactions</i> , 2020, 35, .	0.3	0